Cytek Biosciences (CTKB) Income towards Parent Company (2020 - 2026)

Cytek Biosciences (CTKB) has reported Income towards Parent Company for 7 consecutive years, with -$12.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company fell 118.08% year-over-year to -$12.2 million; the trailing twelve-month figure through Jun 2026 stood at -$80.6 million (down 1155.66% YoY), and the FY2025 full-year result was -$66.5 million, down 1005.3% from the prior year.
• Income towards Parent Company climbed to -$12.2 million in Q2 2026 per CTKB's latest filing, from -$18.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $9.6 million in Q4 2024 and bottomed at -$44.1 million in Q4 2025.
• Historically, Income towards Parent Company has averaged -$6.3 million across 5 years, with a median of -$5.5 million in 2025.
• The widest YoY moves for Income towards Parent Company: up 419.14% in 2022, down 2215.69% in 2022.
• Over 5 years, Income towards Parent Company stood at $3.7 million in 2022, then jumped by 47.18% to $5.5 million in 2023, then surged by 75.49% to $9.6 million in 2024, then sank by 558.98% to -$44.1 million in 2025, then soared by 72.42% to -$12.2 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$12.2 million, -$18.9 million, and -$44.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.